Eli Lilly Dirección

Dirección controles de criterios 2/4

El CEO de Eli Lilly es Dave Ricks , nombrado en Jan 2017, tiene una permanencia de 7.83 años. compensación anual total es $26.57M, compuesta por 6.1% salario y 93.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.067% de las acciones de la empresa, por valor de $475.81M. La antigüedad media del equipo directivo y de la junta directiva es de 6.2 años y 8.4 años, respectivamente.

Información clave

Dave Ricks

Chief Executive Officer (CEO)

US$26.6m

Compensación total

Porcentaje del salario del CEO	6.1%
Permanencia del CEO	7.8yrs
Participación del CEO	0.07%
Permanencia media de la dirección	6.2yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dave Ricks en comparación con los beneficios de Eli Lilly?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Compensación vs. Mercado: La compensación total de Dave($USD26.57M) está por encima de la media de empresas de tamaño similar en el mercado CL ($USD5.72M).

Compensación vs. Ingresos: La compensación de Dave ha aumentado más de un 20% en el último año.

CEO

Dave Ricks (56 yo)

7.8yrs

Permanencia

US$26,565,732

Compensación

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.4yrs	US$11.85m	0.021% $ 152.1m
Anat Hakim	Executive VP	4.8yrs	US$7.01m	0.0034% $ 23.9m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 16.1m
Lucas Montarce	Executive VP & CFO	less than a year	sin datos	0.0012% $ 8.7m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12yrs	sin datos	0.00080% $ 5.7m
Diogo Rau	EVP & Chief Information and Digital Officer	3.5yrs	US$5.10m	0.0012% $ 8.7m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.4yrs	sin datos	0.00088% $ 6.2m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.9yrs	sin datos	0.00093% $ 6.6m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.8yrs	US$5.38m	sin datos
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.3yrs	sin datos	sin datos
Anne White	EVP & President of Lilly Neuroscience	6.2yrs	sin datos	0.0073% $ 51.5m

6.2yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LLY es experimentado (6.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Gabrielle Greene-Sulzberger	Independent Director	3.8yrs	US$335.50k	sin datos
Sidney Taurel	Chairman Emeritus	15.8yrs	US$13.06m	sin datos
Jon Erik Fyrwald	Independent Director	19yrs	US$344.88k	0.000010% $ 70.8k
Ralph Alvarez	Independent Director	15.6yrs	US$336.00k	0.000080% $ 566.4k
William Kaelin	Independent Director	12.4yrs	US$349.15k	sin datos
Mary Hedley	Independent Director	2.5yrs	US$319.00k	0.000040% $ 283.2k
Juan Luciano	Lead Independent Director	8.8yrs	US$373.00k	sin datos
Katherine Baicker	Independent Director	12.9yrs	US$336.00k	sin datos
Jamere Jackson	Independent Director	8.1yrs	US$345.00k	sin datos
Karen Walker	Independent Director	5.9yrs	US$359.00k	sin datos
Kimberly Johnson	Independent Director	3.8yrs	US$316.00k	sin datos

8.4yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de LLY se considera experimentada (8.4 años de antigüedad promedio).

Eli Lilly Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Recent updates

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad